Levosimendan is a drug which increases the sensitivity of the heart to calcium and which opens potassium channels, resulting in inodilation. Clinical trial data from patients suffering from heart failure have demonstrated that it improves haemodynamics without increasing intra-cellular calcium or oxygen consumption. However, there is no consistent evidence of mortality reduction. This narrative review summarises the key trials of its use in acute heart failure, acute coronary syndrome, cardiogenic shock and septic shock.
DicksteinKCohen-SolalAFilippatosG. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J2008;29: 2388–42.
2.
AdamsKFFonarowGCEmermanCL. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J2005;149: 209–16.
3.
ThackraySEasthaughJFreemantleN. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail2002;4: 515–29.
4.
FelkerGMBenzaRLChandlerAB. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol2003;41: 997–1003.
5.
O'ConnorCMGattisWAUretskyBF. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J1999;138: 78–86.
6.
FollathFClelandJGJustH. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360: 196–202.
7.
LehmannABoldtJKirchnerJ. The role of Ca++-sensitizers for the treatment of heart failure. Curr Opin Crit Care2003;9: 337–44.
8.
KivikkoMLehtonenLColucciWS. Sustained hemodynamic effects of intravenous levosimendan. Circulation2003;107: 81–86.
9.
McLeanASHuangSJNalosM. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol2005;46: 830–35.
10.
NieminenMSAkkilaJHasenfussG. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol2000;36: 1903–12.
11.
LillebergJSundbergSHayhaM. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol1994;47: 267–74.
12.
ParissisJTAndreadouIMarkantonisSL. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis2007;195: e210–5.
13.
ParissisJTParaskevaidisIBistolaV. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol2006;98: 1489–92.
14.
ParissisJTAdamopoulosSFarmakisD. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart2006;92: 1768–72.
15.
FlevariPParissisJTLeftheriotisD. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol2006;98: 1641–45.
16.
TziakasDNChalikiasGKHatzinikolaouHI. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovasc Drugs Ther2005;19: 399–402.
17.
ParissisJTAdamopoulosSAntoniadesC. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol2004;93: 1309–12.
18.
UkkonenHSarasteMAkkilaJ. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther2000;68: 522–31.
19.
SlawskyMTColucciWSGottliebSS. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation2000;102: 2222–27.
20.
YilmazMBYontarCErdemA. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels2009;24: 16–21.
21.
DuyguHOzerkanFZoghiM. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract2008;62: 228–33.
22.
DuyguHNalbantgilSOzerkanF. Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clin Cardiol2008;31: 607–13.
23.
AdamopoulosSParissisJTIliodromitisEK. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol2006;98: 102–06.
24.
MoertlDBergerRHuelsmannM. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail2005;7: 1156–63.
25.
MebazaaANieminenMSPackerM. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA2007;297: 1883–91.
26.
ClelandJGFreemantleNColettaAP. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail2006;8: 105–10.
27.
ClelandJGGhoshJFreemantleN. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail2004;6: 501–08.
28.
ColettaAPClelandJGFreemantleN. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail2004;6: 673–76.
29.
FoodyJMFarrellMHKrumholzHM. Beta-blocker therapy in heart failure: scientific review. JAMA2002;287: 883–89.
30.
MebazaaANieminenMSFilippatosGS. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail2009;11: 304–311.
31.
FonarowGCAbrahamWTAlbertNM. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol2008;52: 190–99.
32.
DelaneyABradfordCMcCaffreyJ. Levosimendan for the treatment of acute severe heart failure: A meta-analysis of randomised controlled trials. Int J Cardiol2008;144: 414–15.
33.
MoiseyevVSPoderPAndrejevsN. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J2002;23: 1422–32.
34.
De LucaLProiettiPCelottoA. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J2005;150: 563–68.
35.
SonntagSSundbergSLehtonenLA. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol2004;43: 2177–82.
36.
BocchiEAVilas-BoasFMoreiraMda C. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study. Arq Bras Cardiol2008;90: 182–90.
37.
GreifMZwermannLReithmannC. Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction. Acute Card Care2008;1–6.
38.
RussMAProndzinskyRChristophA. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med2007;35: 2732–39.
39.
Delle KarthGBuberlAGeppertA. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand2003;47: 1251–56.
40.
FuhrmannJTSchmeisserASchulzeMR. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med2008;36: 2257–66.
41.
Samimi-FardSGarcia-GonzalezMJDominguez-RodriguezA. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol2008;127: 284–87.
42.
Dominguez-RodriguezASamimi-FardSGarcia-GonzalezMJ. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol2008;128: 214–17.
43.
Garcia-GonzalezMJDominguez-RodriguezAFerrer-HitaJJ. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail2006;8: 723–28.
44.
RudigerASingerM. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med2007;35: 1599–608.
45.
MorelliADe CastroSTeboulJL. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med2005;31: 638–44.
46.
FlierlMARittirschDHuber-LangMS. Molecular events in the cardiomyopathy of sepsis. Mol Med2008;14: 327–36.
47.
BarraudDFaivreVDamyT. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med2007;35: 1376–82.
48.
HollenbergSMAhrensTSAnnaneD. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med2004;32: 1928.
49.
AvgeropoulouCAndreadouIMarkantonis-KyroudisS. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail2005;7: 882–87.
50.
KyrzopoulosSAdamopoulosSParissisJT. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol2005;99: 409–13.
51.
PintoBBRehbergSErtmerC. Role of levosimendan in sepsis and septic shock. Curr Opin Anaesthesiol2008;21: 168–77.
52.
PowellBPDe KeulenaerBL. Levosimendan in septic shock: a case series. Br J Anaesth2007;99: 447–48.
53.
McLeanAHuangSStewartD. Efficacy of levosimendan in shock. Crit Care2004;8: P83.
54.
MorelliATeboulJLMaggioreSM. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med2006;34: 2287–93.
55.
AlhashemiJAAlotaibiQ. Levosimendan versus dobutamine in septic shock. Crit Care2009;12: 171.
56.
DelgadoJF. Levosimendan in acute heart failure: past, present and future. Rev Esp Cardiol2006;59: 309–12.
57.
FolláthFHinkkaSJägerD. Dose-ranging and safety with intravenous Levosimendan in low-output heart failure: Experience in three pilot studies and outline of the Levosimendan infusion versus Dobutamine(LIDO) trial. Am J Cardiol1999;83: 21–25.
